# Oyster Point Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/oyster-point-pharma

- Industry: Pharmaceuticals
- Headquarters: Princeton, US
- Website: www.oysterpointrx.com
- Total disclosed funding: $114M
- Latest round: Series B (Feb 15, 2019)
- Investors on record: 6

## About

Oyster Point Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies aimed at treating dry eye disease and other related ocular conditions.Founded in 2015 and headquartered in Princeton, US, Oyster Point Pharma, Inc. specializes in ocular therapeutics. The company underwent a successful IPO in October 2019, raising USD 30 mn by selling 5 million shares at USD 16 each. In November 2022, Viatris Inc. agreed to acquire all outstanding shares of Oyster Point Pharma at USD 11 per share, with a potential additional payment contingent on performance. The acquisition, expected to close in early 2023, aims to enhance the reach of the company's products.Oyster Point Pharma focuses on developing therapies for dry eye disease, notably its flagship product, TYRVAYA. The company’s innovative approach addresses the underlying causes of dry eye and aims to improve patient outcomes through effective treatment options.In the most recent fiscal year 2021, Oyster Point Pharma reported a revenue of USD 24.54 mn, while its EBITDA was -USD 95.13 mn, indicating ongoing investment in research and development as it scales its operations.Following the recent acquisition by Viatris, Oyster Point Pharma plans to leverage new resources to enhance the launch and distribution of TYRVAYA. The company aims to expand its product offerings and increase its market penetration in the US and other international markets. The recent funding will be utilized to support the acceleration of its pipeline and enhance the overall impact of its therapies on the dry eye landscape.

## Funding rounds

- Series B, Feb 15, 2019, $85M — KKR, New Enterprise Associates, Versant Ventures, Invus [DUP], Flying L Partners, Vida Ventures
- Series A, Oct 11, 2017, $29M — New Enterprise Associates, Versant Ventures

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A, Series B
- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- KKR (https://capitalatlas.ai/funds/kkr) — Series B
- Invus [DUP] — Series B
- Flying L Partners (https://capitalatlas.ai/funds/flying-l-partners) — Series B
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series B